Kiniksa’s Mavrilimumab Fails In Late-Stage COVID-19 Trial, Doubles Back On Arcalyst

 
• By Ayisha Sharma

The firm’s anti GM-CSF candidate has underwhelmed in a study in hospitalized COVID-19 patients, triggering renewed focus on its recently launched product Arcalyst for recurrent pericarditis.    

White arrows going in one direction, red arrow going in different direction
Analysts Remain Positive About Kiniksa's Value Driver Arcalyst • Source: Alamy

More from Clinical Trials

More from R&D